Skip to content
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP

Tilray Brands, Inc. TLRY

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$915.5M
▲ 11.5% YoY
$-121.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Tilray Brands, Inc. produces, markets and sells beverages; cultivates, produces, distributes and sells both medical and adult-use cannabis products; purchases, resells and distributes pharmaceutical and wellness products; and produces, markets and distributes hemp-based food and other wellness products. It is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America. As of May 31, 2026, it had approximately 3,595 employees worldwide. It reports its operating results in four reportable segments: Beverage, Cannabis, Distribution, and Wellness. Tilray Brands, Inc. was incorporated on January 24, 2018.

Written from the business description in Tilray Brands, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 28 July 2026. Every sentence was checked against that document before publication.

Growth

USD 915.5M
Revenue, FY2025 · full 10-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.9 · Net income -0.1
0.4B0.8B-1.0B-2.0B
2016201920222025
Compound annual growth
+13.4%
+12.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−11 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -6.9% · Net -11.5%
-100%-200%
201620202025
ROE
FY2025 · ROE -7.8%
-100%-200%-300%
201620202025
Three returns, three denominators.

Each USD of equity lost 8 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -127.5
-100M-200M
201620202025

Total assetsUSD 2.3B
EquityUSD 1.6B
CashUSD 226.0M
Gross debtUSD 8.8M
Net debtUSD -217.2M
Current ratio2.21×

The company holds more cash than debt.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TLRY, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.90.80.80.60.60.50.40.20.00.0
Operating income $B−0.1−2.3−0.2−1.4−0.6−0.1−0.1−0.1−0.0−0.0
EBITDA $B◌◌◌◌−0.5−0.1−0.1−0.1−0.0−0.0
Income tax $B0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Net income $B−0.1−2.2−0.2−1.5−0.5−0.4−0.1−0.0−0.0−0.0
Free cash flow $B◌−0.1−0.1−0.0−0.2−0.1−0.2−0.2−0.0−0.0
EPS, diluted $−1.09−24.56−3.30−2.35−0.99−1.36−0.47−0.18−0.10−0.11
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−7.8−88.3−7.2−37.7−10.8−12.9−14.2——−311.8
Shares out B0.131.060.830.660.530.45◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. Nine checks were skipped: EPS is not tagged before 2016. Nine checks were skipped: revenue is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsMay 31
Data on record since2016

Share this section

Download image